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ABSTRACT 26 
Idiopathic dilated cardiomyopathy (iDCM) is a primary myocardial disorder with an unknown 27 
aetiology, characterised by reduced contractility and ventricular dilation of the left or both 28 
ventricles. Naturally occurring canine iDCM was used herein to identify serum proteomic 29 
signature of the disease compared to the healthy state, providing an insight into underlying 30 
mechanisms and revealing proteins with biomarker potential. To achieve this, we used high-31 
throughput label-based quantitative LC-MS/MS proteomics approach and bioinformatics 32 
analysis of the in silico inferred interactome protein network created from the initial list of 33 
differential proteins. To complement the proteomic analysis, serum biochemical parameters 34 
and levels of know biomarkers of cardiac function were measured. Several proteins with 35 
biomarker potential were identified, such as inter-alpha-trypsin inhibitor heavy chain H4, 36 
microfibril-associated glycoprotein 4 and apolipoprotein A-IV, which were validated using an 37 
independent method (Western blotting) and showed high specificity and sensitivity 38 
according to the receiver operating characteristic curve analysis. Bioinformatics analysis 39 
revealed involvement of different pathways in iDCM, such as complement cascade 40 
activation, lipoprotein particles dynamics, elastic fibre formation, GPCR signalling and 41 
respiratory electron transport chain. 42 
KEYWORDS - idiopathic dilated cardiomyopathy, dog, serum, label-based proteomics, 43 
biomarker, bioinformatics 44 
  45 
SIGNIFICANCE 46 
Idiopathic dilated cardiomyopathy is a severe primary myocardial disease of unknown cause, 47 
affecting both humans and dogs. This study is a contribution to the canine heart disease 48 
research by means of proteomic and bioinformatic state of the art analyses, following similar 49 
approach in human iDCM research. Importantly, we used serum as non-invasive and easily 50 
accessible biological source of information and contributed to the scarce data on biofluid 51 
proteome research on this topic. Bioinformatics analysis revealed biological pathways 52 
modulated in canine iDCM with potential of further targeted research. Also, several proteins 53 
with biomarker potential have been identified and successfully validated. 54 
1. INTRODUCTION 55 
Dilated cardiomyopathy (DCM) is a myocardial disorder affecting 1 in 2500 human 56 
individuals and represents the most frequent cause of heart transplantation [1]. It is 57 
characterized by dilation and impaired contraction of the left or both ventricles and carries a 58 
poor prognosis with progression to congestive heart failure or fatal arrhythmias [2]. 59 
Pathologic mechanisms underlying DCM are not understood, especially regarding the 60 
idiopathic form (iDCM), for which the primary cause is unknown. If there is some 61 
evidence/suspicion of the aetiology, DCM is not considered idiopathic, but can be caused by 62 
different contributing factors, such as genetics, nutritional deficiencies, metabolic disorders, 63 
immune system abnormalities, infectious diseases or intoxication [1,3]. Taking into account 64 
DCM is the second most common heart disease of dogs, understanding its mechanisms can 65 
lead to the advances in companion animal veterinary medicine. Also, due to the similarities 66 
between the dog and human cardiovascular system on anatomical, physiological and 67 
molecular level [4], naturally occurring canine iDCM is a suitable model for studying the 68 
human counterpart.  69 
Diagnosis of iDCM is based on echocardiography [5]. Radiography and clinical examination 70 
findings, ECG examination, genetic tests and certain biomarkers circulating in blood, such as 71 
cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), have an 72 
added value in both human and canine iDCM diagnostics. Although serum cTnI and NT-73 
proBNP concentrations are increased in humans and dogs with iDCM, they are not exclusive 74 
biomarkers of this disease and therefore have limited clinical utility [6].  75 
With the development of new high-throughput proteomic technologies, there is a growing 76 
interest in study of new protein biomarkers which could help to diagnose and treat iDCM, 77 
but also unravel underlying pathologic mechanisms. Plasma or serum are especially 78 
promising sources of new easily accessible protein biomarkers since the blood proteome 79 
reflects systemic changes that happen upon organ dysfunction. Proteomic research on both 80 
blood and heart tissue can reveal different aspects of the same condition, encompassing 81 
systemic and local changes taking place during the course of the disease. While there are 82 
some recent studies on myocardial tissue transcriptome and proteome in human iDCM [7,8], 83 
large-scale proteomic analyses of blood which could identify proteins with biomarker 84 
potential in both human and canine iDCM are lacking. To the authors´ knowledge, there is 85 
only one proteomic study of serum of dogs with DCM, where label-free quantitative LC-86 
MS/MS approach was used [9]. 87 
Therefore, we have performed a study of serum proteome changes in iDCM compared to the 88 
healthy state, using naturally occurring canine iDCM as a model, by means of an isobaric 89 
tandem mass tag (TMT) label-based high-resolution quantitative proteomic approach. This 90 
was followed by validation of several biomarker candidates using Western blot. The TMT 91 
label-based approach enables multiplex identification and relative quantification of proteins 92 
between samples in an experimental set by LC-MS/MS. Functional bioinformatics analysis 93 
was also conducted on the acquired dataset in the interest of deeper understanding of 94 
mechanisms involved in iDCM. To complement these analyses, serum biochemical 95 
parameters and serum cTnI and NT-proBNP levels were measured.  96 
2. MATERIALS AND METHODS 97 
2.1. Animals and heart function examination 98 
Two groups of dogs were enrolled in the study in the period between March 2015 and 99 
March 2016: 8 clinically healthy dogs (used as controls) and 8 dogs diagnosed with iDCM. 100 
The study was approved by the Committee on the Ethics of the University of Zagreb, Faculty 101 
of Veterinary Medicine (Permit Number: 640-01/14-305/16, 251-61-01/139-14-28). Healthy 102 
dogs were admitted to the Clinic for Internal Diseases, Faculty of Veterinary Medicine, 103 
University of Zagreb, Croatia, while diseased dogs to the Small Animals Clinic, Department of 104 
Clinical Veterinary Science, Vetsuisse Faculty, University of Bern, Switzerland. All dogs of the 105 
control group underwent clinical examination, haematological and biochemical serum 106 
analyses, as well as cardiac function evaluation performed in unsedated dogs, which 107 
included a 1-minute 6 lead ECG (ASPEL, AsCard Mr. Silver) and transthoracic 108 
echocardiography using Esaote MyLab40 Vet machine and a 5 MHz sector transducer. Dogs 109 
diagnosed with iDCM were enrolled based on the concomitant presence of the two major 110 
criteria for DCM [5]: a) enlarged left ventricular M-mode systolic (LVDs) and  diastolic (LVDd) 111 
dimensions defined according to weight-adjusted values [10] and b) left ventricular M-mode 112 
fractional shortening of <20%. Exclusion criteria were evidence of any other disease than 113 
iDCM based on history, clinical examination, laboratory results or imaging. The cardiac 114 
evaluation of dogs with iDCM included physical examination, thoracic radiographs evaluated 115 
by a board-certified radiologist, a 1-minute 6 lead ECG (Schiller AT 101) and transthoracic 116 
echocardiography performed by a board-certified cardiologist (AK).  Echocardiography was 117 
performed using an Aloka ProSound Alpha 5SV machine and a 5-MHz sector transducer in 118 
unsedated dogs. Echocardiography was performed in a standard manner [11]. Diseased dogs 119 
were classified according to the International Small Animal Cardiac Health Council (ISACHC) 120 
classification system [12]. All procedures were conducted in accordance with EU Directive 121 
2010/63/EU for animal experiments, as well as subject to informed owner consent.  122 
2.2. TMT study  123 
Scheme of the TMT study design is shown in Figure 1. Serum samples collected from 8 dogs 124 
with iDCM and 8 healthy dogs (controls) were all processed and analysed at the same time in 125 
order to reduce inconsistencies. Highly abundant albumin was depleted from all 16 samples 126 
followed by protein concentration determination. An internal standard (IS) was made as a 127 
pool of equal protein amount from all 16 albumin-depleted samples as a reference for 128 
normalization. Equal amount of each protein sample and IS was reduced, alkylated, digested 129 
with trypsin and labelled with TMT reagents. Samples were combined at equal amounts into 130 
4 sets (each consisting of 1 IS, 2 healthy and 2 diseased canine samples) and each set was 131 
analysed by LC-MS/MS. Acquired data was processed statistically to find differentially 132 
abundant proteins, some of which were validated as potential biomarkers of iDCM using 133 
immunoblotting. Also, bioinformatics analysis was performed in order to find pathways 134 
modulated in canine iDCM.  135 
2.3. Serum samples and albumin depletion  136 
Serum was obtained from all 16 dogs by centrifugation of completely clotted blood at 3500 g 137 
for 10 minutes at room temperature. Samples were aliquoted and stored at -80 °C until 138 
analysed. All samples were collected during a one-year period and thawed just once upon 139 
completion of collection, immediately before any analysis. Serum of dogs with iDCM was 140 
collected at the time of initial diagnosis and before any treatment. Before proteomic 141 
analysis, serum samples were depleted by removal of highly abundant albumin using a salt-142 
ethanol precipitation protocol, described by Colantonio et al. [13]. Briefly, 100 µL of each 143 
serum sample was processed by adding 10 µL of 1 M sodium chloride solution (VWR, 144 
Pennsylvania, USA) to yield a final concentration of 0.1 M and incubated with rotation for 1 h 145 
at 4 °C. Cold ethanol absolute (≥99.8%, VWR, Pennsylvania, USA) was then added to yield a 146 
final concentration of 42% and again incubated for 1 h at 4 °C. Samples were centrifuged at 147 
16000 g for 45 min at 4 °C. First pellets were retained and supernatants were further 148 
processed. The pH of the supernatants was lowered to 5.7 by adding cold 0.6 M sodium 149 
acetate buffer (Sigma-Aldrich) of pH 5.6, and incubated for 1 h at 4 °C. Supernatants were 150 
then centrifuged as described above to yield the second pellet. Supernatants (containing 151 
albumin) were removed and the first and second pellets were combined to yield albumin-152 
depleted samples. Pellets were resuspended in 100 mM triethylammonium bicarbonate 153 
buffer (TEAB) (Sigma-Aldrich) containing 1% SDS (Sigma-Aldrich), compatible with further 154 
proteomic analysis. Treated samples were resolved by 1-D SDS PAGE in order to test the 155 
efficiency of albumin depletion procedure for each sample. First, protein concentration was 156 
measured in duplicate using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) per 157 
manufacturer’s guidelines. Samples were then mixed with Laemmli Sample Buffer containing 158 
355 mM 2-mercaptoethanol (Bio-rad) and heated on a heating block for 5 min at 95 °C. The 159 
first well of gel was loaded with 8 μL of PageRuler Plus Prestained Protein Ladder (Thermo 160 
Fisher Scientific) and others with 10 μg of protein per sample. Proteins were separated by 1-161 
D electrophoresis using Criterion TGX precast gels 4–15% (Bio-rad). Gels were run at 300 V 162 
for 20 min in Tris-Glycine-SDS running buffer (Bio-rad). In order to visualise protein bands, 163 
gels were stained with Coomassie Brilliant Blue R-250 solution (Bio-rad), destained in the 164 
destaining solution over night and scanned using UMAX PowerLook III scanner. 165 
2.4. TMT labelling  166 
Amine-reactive Tandem Mass Tags (TMT) isobaric reagents (Thermo Scientific) were used to 167 
label samples in order to multiplex quantification of serum proteins by mass spectrometry 168 
(MS). Samples were grouped into 4 experimental sets in a way that each set contained 169 
albumin-depleted serum sample of 2 healthy dogs, 2 diseased dogs and an internal standard 170 
sample. Internal standard (IS) was used to allow for normalization of data and comparison of 171 
biological replicates between 4 individual pentaplex TMT experiments. One hundred 172 
micrograms of each protein sample and IS samples was prepared and labelled at peptide 173 
level with TMT reagents according to manufacturer’s instructions. In brief, samples were 174 
reduced with 200 mM DTT (Sigma-Aldrich), alkylated with 375 mM iodoacetamide (Sigma-175 
Aldrich) and precipitated with ice-cold acetone (VWR, Pennsylvania, USA) for 4 hours. 176 
Samples were then centrifuged at 8000 g for 10 minutes and acetone was decanted. Pellets 177 
were resuspended with 100 μL of 100 mM TEAB buffer and digested with trypsin (Promega) 178 
overnight at 37 °C (2.5 μg of trypsin per 100 μg of protein). Thereafter, IS peptide samples 179 
were labelled with TMT-126 reagent, while other 16 peptide samples were labelled 180 
randomly with TMT-127, TMT-128, TMT-129 and TMT-130 reagents to avoid possible 181 
labelling preference. TMT label reagents were equilibrated to room temperature, dissolved 182 
in anhydrous acetonitrile, LC-MS grade (Thermo Scientific) for 5 minutes with occasional 183 
vortexing and added to each sample (41 μL of the reagent to 100 μg sample). Labelling 184 
reaction was incubated for 1 hour at room temperature and then quenched by adding 5% 185 
hydroxylamine (Thermo Scientific) for 15 minutes. Samples were then combined at equal 186 
amounts into 4 pentaplex sets (as described above) and 6 μg of each mixed sample set was 187 
placed in a well of a microplate. Samples were vacuum-dried for 15 minutes and stored at -188 
20 °C before further LC-MS/MS analysis. 189 
2.5. LC-MS/MS analysis 190 
The LC−MS/MS analysis was performed on Dionex Ultimate 3000 RSLS nano flow system 191 
(Dionex, Camberley, UK) and Orbitrap Elite mass spectrometer (Thermo Fisher Scientific). 192 
TMT-labelled peptide mixtures were reconstituted in buffer A (2% acetonitrile in 0.1% formic 193 
acid). An amount of 3 μg was loaded on the trapping column C18 PepMap100 (5 μm, 100 A, 194 
300 μm x 5 mm) and then separated using C18 RSLC PepMap ID column (15 cm x 75 μm) 195 
with linear gradient 5-35% buffer B (0.1% formic acid in 80% acetonitrile) over 135 min at a 196 
flow rate of 300 nL/min. Eluate from the column was introduced to the Orbitrap Elite MS. 197 
The ionisation voltage was set to 1.7 kV and the ion transfer tube temperature to 220 °C. MS 198 
was operating in positive ion mode using collision-induced dissociation/higher energy 199 
collisional dissociation CID/HCD fragmentation methods for MS2. Full scan Fourier 200 
transform-based mass spectrometry (FTMS) spectra were acquired in range from m/z 380.0 201 
to 1800.0 with resolution of 60000. The maximum injection time for FTMS full scan was set 202 
as 200 ms reaching an automatic gain control (AGC) target value of 1x106. Three most 203 
intense peaks from MS spectrum were selected for each fragmentation mode. Ions with the 204 
charge state 1+ were excluded from the fragmentation list. The HCD MS/MS scan was fixed 205 
to start from m/z 100.00 with resolution of 15000 using MS2 AGC target of 5x104. The 206 
collision energy was set as 40% normalized collision energy (NCE). Isolation window of ± 1.5 207 
Da was applied to isolate precursor ions with dynamic exclusion of 20 s. Every precursor ion 208 
was repeated twice within duration time of 30 s and was excluded for 20 s. Ion trap mass 209 
spectrometry CID MS/MS scan spectra were acquired with 35% NCE and an AGC target of 210 
1x104. 211 
2.6. MS/MS data analysis 212 
Acquired MS/MS spectra were analyzed for protein identification and quantification using 213 
Proteome Discoverer software 2.1 (Thermo Fisher Scientific). Protein identification was 214 
performed using the Mascot algorithm against the Canis lupus familiaris protein database 215 
from NCBInr (version 04/05/2016; 41195 sequences), with a precursor mass tolerance of 10 216 
ppm and fragment ion mass tolerance of 0.8 Da. Set modifications were addition of TMT 6-217 
plex labels to lysines and N-termini, carbamidomethylation of cysteine as fixed modification 218 
and methionine oxidation as variable modification. Two missed cleavages for the trypsin 219 
digestion were permitted. Identified peptides were filtered with a cut-off criterion of a q-220 
value of 0.01, corresponding to a 1% false-discovery rate (FDR) for highly confident peptide 221 
hits and a q-value of 0.05 (5% FDR) for peptide hits with moderate confidence. 222 
Quantification was performed using abundances of reporter ions based on signal to noise 223 
ratio values or intensity. Normalization was carried out based on total peptide amount and 224 
scaling on channels average. Abundances of reporter ions from only unique and razor 225 
peptides were used to estimate the abundances of proteins. Identification and quantification 226 
data were exported from Proteome Discoverer to Microsoft Excel software. Abundances 227 
ratios were obtained for each protein by comparing with values of corresponding internal 228 
standard and then used to calculate average fold change ratio between healthy and iDCM 229 
groups. Internal standard-normalized protein abundances ratios were used in statistical 230 
analysis to detect significant differences between the studied groups. 231 
2.7. Validation of proteomics results 232 
 233 
Validation of proteomics results was performed by Western blotting using the non-depleted 234 
serum samples of the same patients as in proteomic analysis. In brief, 25 μg of proteins of 235 
each serum sample (8 healthy controls and 8 iDCM) was boiled at 95 °C for 5 minutes in SDS-236 
loading buffer and separated over 4-10% polyacrylamide gel. Proteins were then transferred 237 
to nitrocellulose membranes (Amersham Protran, GE Healthcare) for 2 h at 50 mA in 20% 238 
methanol (Sigma) transfer buffer at 4 °C using Biostep electro blotting module. After the 239 
transfer, gels were stained with Coomassie Brilliant Blue G-250 (Amresco) in order to verify 240 
equal transfer and to use protein load as a reference for protein quantity normalization. The 241 
membranes were blocked for 1 h with 5% skim milk (VWR, Pennsylvania, USA) in Tris 242 
buffered saline (pH=7.6) containing 0.05% Tween20 (Sigma) at room temperature. The 243 
membranes were then incubated overnight at 4 °C with primary antibodies to ITIH4 (dilution 244 
1:5000, kindly provided by F. Lampreave group, University of Zaragoza), ITIH3 (1:200, Santa 245 
Cruz Biotech, sc-21979), MFAP4 (1:500, Aviva Systems Biology, ABIN2776850), TfR1 (1:500, 246 
Covalab, pab75255), APOA4 (1:250, Biorbyt, orb5708) and AGT (1:500, Aviva Systems 247 
Biology, ABIN2781494). Specific polyclonal rabbit antiserum against the purified canine ITIH4 248 
was raised by F. Lampreave group [14]. The ITIH3, MFAP4, TfR1, APOA4 and AGT antisera 249 
were not raised towards corresponding canine proteins, but had predicted cross-reactivity 250 
based on the immunogen amino acid sequence homology (as stated by the manufacturers). 251 
After washing, membranes were incubated for 1h at room temperature with appropriate 252 
secondary antibody (dilution 1:5000, donkey anti-goat IgG, sc-2020 and goat anti-rabbit sc-253 
2004, Santa Cruz Biotech) conjugated with horseradish peroxidase. Immunostained proteins 254 
were detected by incubation with Western blotting luminol reagent (Santa Cruz Biotech) for 255 
8 min and recorded in chemiluminesence mode using Li-Cor Odyssey Fc (Li-Cor, Inc). 256 
Acquired figures were analysed using ImageJ software (US National Institutes of Health, 257 
Bethesda, Maryland, USA) and differences between healthy and diseased dogs determined 258 
using unpaired t test, with p value < 0.05 considered statistically significant.    259 
2.8. Serum biochemical parameters  260 
One serum aliquot was used for measurement of biochemical parameters using commercial 261 
reagents (Beckman Coulter) per manufacturer´s instructions in an automatic analyser 262 
(Olympus AU640, Japan). The following parameters were measured: serum urea, creatinine, 263 
bilirubin, glucose, proteins, albumin, aspartate aminotransferase, alanine aminotransferase, 264 
gamma-glutamyl transferase, alkaline phosphatase, creatine kinase, lactate dehydrogenase, 265 
C-reactive protein, alpha-amylase, lipase, cholesterol, triglycerides, calcium, magnesium, 266 
phosphates.  267 
 268 
2.9. Measurement of cTnI and NT-proBNP blood concentration 269 
Cardiac troponin I (cTnI) was measured in serum samples of control (N=8) and iDCM (N=8) 270 
group using commercially available ADVIA Centaur TnI-Ultra assay, which is a high-sensitivity 271 
immunoassay validated for use in both humans and dogs [15]. Analysis was performed in 272 
Dubrava Clinical Hospital, Department of clinical diagnostics (Zagreb, Croatia) using Siemens 273 
Advia Centaur XP according to manufacturer´s instructions. Samples which had serum 274 
concentration of cTnI below the lower level of detection of the assay were allocated a value 275 
of 0.01 μg/L. Analysis of NT-proBNP concentration in all 16 samples was performed in Vet 276 
Med Labor GmbH, reference IDEXX Laboratory (Germany) using IDEXX Cardiopet® proBNP 277 
test.  278 
2.10. Statistics  279 
Statistical analyses were performed using the R software version 3.3.1 [16]. Statistical 280 
differences in the age, sex, protein abundances ratios acquired in proteomic analysis, serum 281 
biochemical parameters and cTnI and NT-proBNP levels between healthy and iDCM groups 282 
were determined using nonparametric Mann-Whitney test. In order to compare healthy 283 
group, iDCM ISACHC class II and iDCM ISACHC class IIIA, the nonparametric Kruskal-Wallis 284 
and Dunn post hoc test were used. For all statistical comparisons, p < 0.05 was considered 285 
statistically significant. In order to test sensitivity and specificity of potential protein 286 
biomarkers according to proteomic analysis, receiver operating characteristic (ROC) curve 287 
analysis was performed and area under the curve (AUC) computed using MedCalc for 288 
Windows, version 18.0 (MedCalc Software, Ostend, Belgium). The required sample size for 289 
the comparison of the area under a ROC curve with a null hypothesis value was calculated 290 
using following parameters: null hypothesis value = 0.5, type I error (alpha, significance) = 291 
0.05, type II error (beta, 1-power) = 0.2. 292 
2.11. Bioinformatics analysis 293 
Proteins with significantly differential abundances observed by proteomic and serum 294 
biochemical analyses (in total N=15) were further functionally analyzed using bioinformatics 295 
tools. As human database is more complete than canine one (reviewed proteins in 296 
UniprotKB/Swiss-prot release 2018_01: humans 20259, dogs 817), dog’s proteins were 297 
converted to human proteins by performing BLAST (protein-protein BLAST) analysis of 15 298 
identified canine proteins using human protein database (UniprotKB/Swiss-prot release 299 
2017_10). The best matching protein (ID score, query coverage and E-value) was considered 300 
as ortholog for each canine protein in the initial list. Then, an enriched network of proteins 301 
was built based on the list of the initial 15 proteins, adding a maximum of 40 best interactors 302 
(using the following combination of Homo sapiens database: IntAct, Reactome, and String-303 
database) with the Cytoscape (v3.5.1) application Cluepedia (v1.3.5). All types of interactions 304 
were considered. Clusters of interacting proteins were calculated by the Cytoscape 305 
application MCODE (v1.4.2), with node cutoff at 0.3 and K-core at 4. Thereafter, pathway 306 
analysis of each cluster was performed using the Cytoscape (v3.5.1) plugin ClueGO (v2.3.5). 307 
Ontology used was Reactome-Pathways (21/10/2017). P-value of each term was corrected 308 
with Bonferroni step-down. Pathway terms groups were defined according to the kappa 309 
score (threshold at 0.6) and sharing group percentage at 50%. Pathways leading term of 310 
each group was determined by its p-value. After determining Pathway terms for each 311 
cluster, terms were merged if they were identical or one term had a higher hierarchical 312 
position than another term. For the latter, the upper hierarchical Pathway term was 313 
considered as the leader term. Hierarchical orders were accessed using the Reactome.org 314 
database. Complete networks of each identified Pathway terms (available on Reactome.org 315 
with all proteins/genes and chemicals) were merged to constitute the in silico inferred 316 
interactome network of molecular processes from the initial 15 proteins. Using this in silico 317 
inferred interactome network, pathways and cellular compartment analyses were 318 
performed. Pathways analyses used the Reactome-Pathways (21/10/2017) with following 319 
parameters: evidence codes used “All_Experimental”, Kappa score threshold 0.4, number of 320 
genes = 30, minimum percentage = 70, p-value correction used = Bonferroni step down. 321 
Cellular compartment analyses used the GO-CellularComponent-EBI (27/10/2017), with 322 
following parameters: evidence codes used “All_withoutIEA”, Kappa score threshold 0.5, 323 
number of genes = 20, minimum percentage = 15, minimum GO level = 3, Maximum GO level 324 
= 10, p-value correction method used = Bonferroni step down. 325 
 326 
 327 
 328 
 329 
 330 
3. RESULTS 331 
3.1. Animals and heart function  332 
 333 
The control group consisted of 8 healthy dogs with normal cardiac function, aged from 5 to 334 
12.5 years of following breeds: 2 Belgian shepherds, 1 Border collie, 1 Beauceron, 1 Flat-335 
coated retriever, 1 Labrador retriever and two mixed-breed dogs (25 and 38 kg). Three dogs 336 
in the control group were male, 1 was male castrated and 4 were female spayed. During the 337 
13 months of the study, 8 adult dogs were diagnosed with iDCM at the co-authors´ (AK) 338 
institution. In the diseased group there were dogs of either sex, aged between 3 and 7 years. 339 
These were 1 mixed breed dog (40 kg) and 7 dogs from 5 different breeds (2 German 340 
shepherds, 1 Doberman, 1 Cane Corso Italiano, 1 Leonberger, 1 Bouvier des Flandres and 1 341 
Great Dane).  Two dogs were female, 2 female spayed, 1 male und 3 male castrated. There 342 
was no statistical difference in the age between the control (median; interquartile range: 8.5 343 
years; 5.5-10.75) and iDCM (7 years; 7-7.75) group. If the neutering is disregarded, there was 344 
also no difference in the sex between the groups (each group consisted of 4 males and 4 345 
females). At initial physical examination all dogs of iDCM group were considered in heart 346 
failure based on elevated respiratory rate and effort, signs of interstitial or interstitial-347 
alveolar lung pattern and absolutely dilated pulmonic veins on the thoracic radiographs. 348 
Four dogs were classified as ISACHC class II and four dogs as ISACHC class IIIA. In accordance 349 
with the ISACHC classification system, dogs in class II group presented with a mild to 350 
moderate heart failure, while dogs in class IIIA presented with an advanced heart failure. A 351 
grade II-VI left-sided systolic heart murmur was identified in all diseased dogs. Six dogs were 352 
in atrial fibrillation with a ventricular heart rate 150-240/min. Two of those dogs had rare 353 
ventricular premature complexes (VPC) and one dog a left bundle branch block (LBBB).  Two 354 
dogs showed a sinus rhythm 150/min respec. 160/min. According to the inclusion criteria, 355 
echocardiographic examination showed abnormal left ventricular end diastolic (Figure 2a) 356 
and end systolic diameter (Figure 2b) and reduced fraction shortening (8-16%). The left 357 
atrial/aorta ratio (LA:Ao) was enlarged (1.8-3) in all dogs and all showed some functional 358 
mitral regurgitation, while 5 dogs an additional functional tricuspidal regurgitation.  359 
 360 
                      361 
3.2. Albumin depletion 362 
 363 
The most abundant serum protein albumin, which could mask identification and 364 
quantification of low abundant proteins in downstream proteomic analysis, was removed 365 
with good reproducibility and efficiency from all 16 canine serum samples using salt-ethanol 366 
precipitation protocol, verified by 1-D SDS PAGE. Figure 3 shows that the intensity of the 367 
dominant band corresponding to albumin (~68 kDa) in non-depleted canine serum 368 
decreased remarkably in both healthy and diseased serum samples after the depletion 369 
procedure. 370 
 371 
3.3. Protein identification and quantification using TMT approach 372 
In this study, 4 pentaplex experimental sets containing 16 different samples (plus IS samples) 373 
were analysed using TMT label-based quantification approach. Since an IS was used in each 374 
set, it was possible to use it as a normalization reference and compare protein quantities 375 
detected in more than one set across different TMT runs. In total, 358 proteins were 376 
identified with high and medium confidence by combining all data from 4 sets. These 377 
proteins were grouped by the Proteome Discoverer software into 134 groups, with the top-378 
ranking protein of the group listed as the master protein. Of 134 master proteins, 129 were 379 
identified with high (1% FDR) and 5 with medium (5% FDR) confidence, while quantification 380 
values were obtained for 131 proteins. Only highly confident master proteins (1% FDR), 381 
identified and quantified by 2 or more unique peptides and detected in at least 4 biological 382 
replicates were selected for the quantification analysis, which included 76 proteins (list 383 
provided as supplemental Table 1). For these proteins the average abundance fold change 384 
(iDCM/healthy ratio) ranged from 0.5 to 2. There was one protein (microfibril-associated 385 
glycoprotein 4, MFAP4) where exception was made in terms of criterion for the number of 386 
unique peptides. Although MFAP4 was identified and quantified by only one unique peptide, 387 
there was a remarkable fold change (1.6) so it was included in the statistical analysis, and its 388 
differential abundance between the groups was later tested by Western blotting. When 389 
nonparametric Mann-Whitney test was applied, 12 proteins showed significantly different 390 
levels (p < 0.05) in iDCM versus control serum with the fold changes ≥1.2 or ≤0.8 (Table 1). 391 
Of those 12 proteins, microfibril-associated glycoprotein 4 (MFAP4), inter-alpha-trypsin 392 
inhibitor heavy chain H4 (ITIH4) and apolipoprotein A-IV (APOA4) were also significantly 393 
different (p < 0.05) between the controls, iDCM ISACHC II and iDCM ISACHC IIIA groups 394 
(Figure 4). 395 
 396 
Table 1. Proteins with significantly differential abundances between healthy dogs and dogs 397 
with iDCM identified in serum using TMT approach. 398 
GI 
accession 
number* 
Description 
N of 
unique 
peptides 
Mascot 
score 
Fold change 
(iDCM/healthy) 
p-value 
(iDCM 
versus 
healthy) 
N of 
detections** 
Upregulated 
928186325 
inter-alpha-trypsin 
inhibitor heavy chain H4 
 
21 3170 2 0.0003 
 
16 
73956164 
microfibril-associated 
glycoprotein 4 
 
1 369 1.6 
 
0.0043 
 
12 
928186331 
inter-alpha-trypsin 
inhibitor heavy chain H3 
 
3 126 1.6 
 
0.0286 
 
8 
545494757 
angiotensinogen 
 
5 866 1.2 0.0207 
 
16 
928150787 
complement C4-A 
 
52 16701 1.2 
 
0.0379 
 
16 
545496317 
 
complement 
component C9 
 
2 245 1.2 0.0379 
 
16 
928159887 
 
plasma protease C1 
inhibitor 
4 2194 1.2 0.0499 16 
Downregulated 
345799905 
 
apolipoprotein A-IV 
 
19 3621 0.6 
 
0.0019 
 
16 
17066524 
 
immunoglobulin 
gamma heavy chain A 
 
5 7053 0.6 0.0499 
 
16 
924859480 
 
apolipoprotein C-III 
precursor 
4 1521 0.7 0.0379 
 
16 
50978812 
 
transferrin receptor 
protein 1 
2 141 0.8 0.0379 
 
16 
928133662 
 
apolipoprotein A-I 
26 45231 0.8 0.0499 
 
16 
*accession number from NCBI protein database for Canis lupus familiaris 399 
**number of samples in which the protein was detected 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
3.4. Validation of proteomics results  409 
 410 
In order to verify differences in serum protein abundances observed by proteomic analysis, 5 411 
selected proteins were validated by Western blotting using total protein load as 412 
normalization reference. Consistent with TMT based proteomics results, the relative 413 
abundances of ITIH4, ITIH3 and MFAP4 were significantly increased in iDCM group compared 414 
to controls, while those of TfR1 and APOA4 were decreased (Figure 5, p<0.05). 415 
Angiotensinogen (AGT) relative abundance increase according to proteomic analysis was 416 
also tested by imunoblotting, but there was no significant difference between the groups 417 
(data not shown). We were not able to confirm our observation possibly due to the 418 
existence of AGT glycoprotein forms in canine plasma [17], requiring different method of 419 
validation, such as 2-D Western blotting. 420 
3.5. Serum biochemistry  421 
Values of serum biochemical parameters which were significantly different between dogs 422 
with iDCM and healthy dogs are presented in Table 2. C-reactive protein (CRP), urea and 423 
triglycerides concentrations, as well as creatine kinase (CK) and lactate dehydrogenase (LDH) 424 
activities, were significantly increased in serum of dogs with iDCM compared to healthy 425 
dogs. There were no significant differences in other analysed parameters: creatinine, 426 
bilirubin, glucose, proteins, albumin, aspartate aminotransferase, alanine aminotransferase, 427 
gamma-glutamyltransferase, alkaline phosphatase, alpha-amylase, lipase, cholesterol, 428 
calcium, magnesium and phosphates. 429 
Table 2. Serum biochemical parameters with significantly differential values between 430 
healthy dogs and dogs with iDCM. 431 
Parameter Healthy group iDCM group Reference range 
C-reactive protein (mg/L) 0 (0 - 0.3) 9.1 (8.5 - 20.1)** 0 - 10.7 
Creatine kinase (U/L) 75 (69-123) 163 (132 - 460)* 0-160 
Lactate dehydrogenase (U/L) 64 (37-68) 141 (106 - 228)* 45 - 233 
Urea (mmol/L) 5.2 (4.4 - 5.6) 8.4 (6.2 - 17.9)* 3.3 - 8.3 
Triglycerides (mmol/L) 0.6 (0.3 - 0.7) 0.9 (0.6 - 1.5)* 0.2 - 1.3 
The results are expressed as median and interquartile range. 432 
Outliers were excluded based on box plot (CRP, LDH and CK - 1 outlier in each group). 433 
*p < 0.05, **p < 0.01 (compared to the control group)  434 
3.6. Measurement of cTnI and NT-proBNP blood concentration 435 
Concentrations of serum cTnI, as well as plasma NT-proBNP, were significantly increased in 436 
dogs with iDCM when compared to the control group (Figure 6a and 6b, respectively). 437 
 438 
3.7. Bioinformatics analysis 439 
 440 
Figure 7 displays the workflow of the bioinformatics analysis. All 15 differentially abundant 441 
canine proteins (according to proteomic (N=12) and serum biochemistry (N=3) analyses) 442 
were successfully mapped to Homo sapiens protein orthologs (supplemental Table 2). Then, 443 
enrichment added 334 proteins/genes to the initial 15 proteins, with best interactors 444 
matching defined criteria. All 15 initial proteins were connected to the network. In this 445 
network, 10 different clusters were defined (supplemental Table 2). All clusters were defined 446 
by at least 1 Pathway term. A group of 135 nodes was not able to form a cluster and 447 
therefore named Non-clustered, and was characterized by 4 Pathways terms. Since different 448 
clusters exhibit same Pathways terms or terms belong to the same upper hierarchical order 449 
term, some terms were merged. After merging terms from clusters, 19 pathways were 450 
identified (supplemental Table 2). All 19 Pathways terms were merged to establish the 451 
inferred interactome network, with 1341 nodes (1230 genes/proteins and 111 chemicals). 452 
All Pathways terms were connected to the network, with the exception of some parts of the 453 
Chemokine receptors bind chemokines term. Finally, Reactome Pathways terms analysis was 454 
performed on the whole inferred network, resulting with 15 identified terms (Table 3) which 455 
were grouped according to their roles into 4 groups (Figure 8). These groups were Signal 456 
transduction GPCR signaling, Immune system/Platelet, Vesicles transport and Metabolism. 457 
Furthermore, GO Cell localization terms analysis of the whole inferred network identified 17 458 
mostly associated cell localizations terms (Table 4). 459 
 460 
 461 
 462 
 463 
Table 3. Pathways terms (Reactome) identified on the whole in silico inferred network.  464 
Pathways term Term P-value Network Nodes 
G alpha (i) signalling events 8.23E-196 223 
The citric acid (TCA) cycle and respiratory electron transport 6.91E-95 131 
Clathrin-mediated endocytosis 4.45E-103 123 
Response to elevated platelet cytosolic Ca2+ 5.75E-102 120 
PPARA activates gene expression 3.72E-91 107 
Anchoring of the basal body to the plasma membrane 6.66E-71 86 
Clathrin derived vesicle budding 8.46E-66 70 
Plasma lipoprotein assembly, remodeling, and clearance 2.69E-54 63 
Complement cascade 6.89E-44 52 
Chemokine receptors bind chemokines 2.71E-42 46 
G alpha (z) signalling events 1.55E-33 41 
Retinoid metabolism and transport 1.77E-33 39 
Formation of Fibrin Clot (Clotting Cascade) 1.43E-33 37 
Elastic fibre formation 5.29E-26 35 
Class C/3 (Metabotropic glutamate/pheromone receptors) 1.36E-24 31 
 465 
 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
 474 
 475 
 476 
 477 
 478 
 479 
 480 
Table 4. GO Cell localization terms of the in silico inferred network. 481 
GO Cell localization term Term P-value Network nodes 
cytoplasmic vesicle part 7.99E-56 257 
membrane protein complex 6.11E-53 167 
lysosome 2.79E-20 114 
endosome 1.33E-13 108 
cell surface 4.18E-16 107 
platelet alpha granule 9.05E-75 81 
inner mitochondrial membrane protein complex 5.43E-43 67 
secretory granule membrane 1.02E-07 52 
plasma membrane protein complex 5.69E-13 49 
trans-Golgi network 1.41E-07 38 
early endosome 8.19E-05 36 
microtubule organizing center part 1.95E-07 31 
proton-transporting two-sector ATPase complex 1.62E-24 30 
azurophil granule 9.37E-05 28 
clathrin-coated pit 1.23E-23 28 
lysosomal lumen 2.46E-07 25 
phagocytic vesicle 5.66E-06 21 
 482 
3.8. The performance of biomarkers 483 
In order to test the discriminatory power of the 12 differentially abundant proteins between 484 
the groups, ROC curves were constructed and AUC calculated, but only 4 proteins fulfilled 485 
the criterion of the required sample size (ITIH4, ITIH3, MFAP4 and APOA4). The ROC curves, 486 
AUC values, p values, sensitivity and specificity with corresponding criterion for those 4 487 
proteins are shown in the Figure 9. All 4 proteins yielded high AUC values (above 0.9), as well 488 
as sensitivity and specificity indicating their good performance as potential biomarkers of 489 
iDCM in dogs. 490 
 491 
 492 
 493 
4. DISCUSSION 494 
Using the TMT label-based relative quantification proteomics approach, we have found 12 495 
differentially abundant serum proteins between dogs with iDCM and healthy dogs. Identified 496 
differences indicate involvement of several physiological pathways in studied disease, such 497 
as complement activation, acute phase response, lipoprotein particles dynamics and tissue 498 
remodelling. Furthermore, bioinformatics analysis revealed an impact on some metabolic 499 
and signalling processes, such as ˝The citric acid cycle and respiratory electron transport˝ 500 
and ˝Signal transduction GPCR signalling˝. 501 
Several components of the innate immune system response were found to be up-regulated 502 
by proteomic analysis in iDCM compared to healthy patients: complement C4-A, 503 
complement component C9, plasma protease C1 inhibitor (C1-INH) and newly recognized 504 
acute-phase response proteins inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) and H4 505 
(ITIH4). Components of the complement system C4-A and C9, as well as complement 506 
regulatory protein C1-INH, were significantly increased in dogs with iDCM, but with the 507 
average fold change (iDCM/healthy ratio) of only 1.2, which suggests the activation of the 508 
complement cascade in dogs with iDCM is present, at least in some of the patients studied. 509 
Complement protein C4 is an early component of the cascade activated through the classical 510 
or lectin pathway, while complement protein C9 is one of the components of the membrane 511 
attack complex (MAC) in the terminal pathway [18].  512 
Up-regulation of positive acute-phase response (APR) proteins ITIH4 and ITIH3 detected in 513 
serum of dogs with iDCM suggests there is an activation of APR in the setting of heart tissue 514 
injury. Acute phase response (APR) is an immediate, nonspecific and complex defensive 515 
reaction which develops in an animal upon any tissue injury (caused by infection, 516 
inflammation, neoplasia, trauma or other causes) in order to restore homeostasis. During 517 
the APR, pro-inflammatory cytokines stimulate the production of positive acute-phase 518 
proteins (APPs) in hepatocytes leading to increase in their plasma concentration [19]. ITIH3 519 
was shown to be up-regulated in human liver upon inflammation mediated by interleukin-1 520 
and interleukin-6 [20]. ITIH4 is a major APP in pigs which is specifically induced in 521 
hepatocytes by interleukin-6 [21,22]. ITIH4 was also elevated in serum of cows with both 522 
experimentally induced and naturally occurring mastitis [23,24]. Recently, it was found to be 523 
a new positive APP in dogs where major surgery was used as an inflammatory model [14]. 524 
Both ITIH3 and ITIH4 bind covalently to hyaluronan, thereby promoting its stabilization. 525 
Hyaluronan is one of the main components of extracellular matrix in vertebrates which is 526 
involved in cell migration and tissue repair upon injury [25]. Increased levels of ITIH3 and 527 
ITIH4 found in our study could be due to the need of extracellular matrix stabilization in 528 
heart tissue of diseased dogs. Additionally, ITIH4 could have anti-inflammatory effects since 529 
it may have a role in complement suppression [25].  530 
Our finding of significantly increased concentration of C-reactive protein (CRP) in iDCM 531 
group compared to healthy (measured by serum biochemistry test) also provides evidence 532 
for activation of APR in iDCM. CRP is a well known major positive APP in both humans and 533 
dogs, used as sensitive, but nonspecific biomarker of systemic inflammation [26]. This study 534 
contributes to the rare reports of serum CRP concentration evaluation in dogs with iDCM, 535 
but with limitation of a small sample size and remark that some values in iDCM group didn´t 536 
exceed the upper limit of the normal reference range. Similar results were observed in a 537 
study of dogs with chronic valvular disease (CVD), the most common acquired heart disease 538 
of the dog, where CRP concentration was significantly higher in dogs with CVD compared to 539 
healthy dogs, but with a large degree of overlap between the two groups [27]. Increased 540 
plasma CRP concentrations were also found in dogs with congestive heart failure due to 541 
mitral valve disease or dilated cardiomyopathy compared to controls, but only 5 dogs with 542 
DCM were included [28]. In a study of human patients with iDCM, serum CRP levels were 543 
increased compared to controls [29]. 544 
While there is widening evidence of role of immune processes in a portion of human DCM 545 
cases [30], such findings are poorly documented in canine DCM research. However, in a 546 
study of Buse et al. [31] there were significantly higher levels of serum auto-antibodies 547 
against myosin heavy chain and α-cardiac actin in dogs with DCM than in controls, while Day 548 
[32] found anti-mitochondrial antibodies in one third of examined English Cocker Spaniels 549 
with DCM. Results of our study support the notion that immunological processes are also 550 
involved in the pathopshysiology of canine iDCM, although sequence of events leading to 551 
their involvement in the disease cannot be clearly elucidated. 552 
Apolipoproteins A1 (APOA1), A4 (APOA4) and C3 (APOC3), which are lipid-binding proteins 553 
involved in the transport of lipids in plasma, were found to be down-regulated in iDCM 554 
compared to control serum in our study. Lower plasma APOA1 levels were also found in 555 
human patients with iDCM compared to controls [29,33]. APOA1 is a major constituent of 556 
high-density lipoprotein particles which was found to have anti-inflammatory properties 557 
since it may interfere with the assembly of complement C9 of the MAC of complement 558 
cascade [34]. APOA4 is a protein found free in plasma or as a component of different 559 
lipoprotein particles, which was shown to have anti-atherogenic and antioxidative 560 
properties. Lower levels of APOA4 were found in human patients with cardiovascular disease 561 
compared to controls and low APOA4 levels predicted the risk for sudden cardiac death in 562 
patients with high risk [35]. It is possible that reduced levels of APOA1 and APOA4 detected 563 
in dogs with iDCM contribute to the development or advancement of the disease and could 564 
be potentially used as a risk biomarker. 565 
Interesting finding of increased serum microfibril-associated glycoprotein 4 (MFAP4) levels in 566 
dogs with iDCM could have origin in remodelling processes taking place in dilated 567 
myocardium. MFAP4 is an extracellular matrix (ECM) glycoprotein expressed in various 568 
elastic tissues which has a role in elastic fiber organization [36]. Increased serum levels of 569 
MFAP4 were proposed to be a potential biomarker in pathologies characterised by ECM 570 
remodelling, such as liver fibrosis in hepatitis C patients [37]. MFAP4 was also found to be 571 
elevated in plasma of human patients with congestive heart failure [38]. In a proteomic 572 
study of serum glycoproteins in canine model of dyssynchronous heart failure, MFAP4 was 573 
upregulated when compared to control dogs [39]. It is well known that, in the setting of both 574 
human and canine iDCM, heart tissue is undergoing fibrosis which involves ECM degradation 575 
and remodelling [40,41]. We show herein that serum level of MFAP4 could serve as 576 
biomarker of heart tissue remodelling in iDCM. 577 
Transferrin receptor protein 1 (TfR1) is a membrane glycoprotein which has a role in 578 
transport of iron from plasma to cell and whose expression on the surface of cells is 579 
dependent on tissue iron status. Serum TfR1 (sTfR1) represents the soluble extracellular 580 
portion of TfR1 whose level reflects TfR1 density on cells (i.e. iron status) and the number of 581 
cells expressing TfR1 (i.e. mostly cells with erythropoietic activity). Levels of sTfR1 are used 582 
as biomarker in iron deficiency and anaemia of chronic disease in humans [42]. We detected 583 
slightly decreased levels of sTfR1 in diseased dogs compared to healthy, which could suggest 584 
a change of erythropoietic activity or iron status in iDCM. Although anaemia is not common 585 
finding in dogs with iDCM, it is present in certain number of diseased dogs [43,44]. 586 
Increased serum abundances of angiotensinogen (AGT) in dogs with iDCM are not a 587 
surprising finding since AGT is a part of the renin-angiotensin-aldosterone system (RAAS), 588 
which is known to be activated in dogs with DCM, although only in those with clinical signs 589 
(the New York Heart Association (NHYA) class III and IV) [45,46].  AGT production in dogs is in 590 
some minor extent stimulated by positive feedback by its final product angiotensin II at 591 
physiological conditions [47]. Dogs with iDCM included in our study were classified to the 592 
NHYA class II and III, which could explain for only slight elevation of serum AGT in 593 
comparison to healthy dogs. While serum AGT elevation in the diseased group in our study 594 
indicates activation of the RAAS, increase of specifically measured plasma NT-proBNP herein 595 
also points out to the natriuretic system stimulation in dogs with iDCM. NT-proBNP was 596 
found to be elevated in both humans and dogs with DCM [48]. Elevated NT-proBNP 597 
concentrations are detected in blood as a response to different factors, such as volume 598 
overload, hypertrophy and hypoxia. Actions of natriuretic system lead to natriuresis and 599 
vasodilation, acting in contrary to the RAAS, which induces sodium retention and 600 
vasoconstriction. It is known that activities of both systems contribute to the congestive 601 
heart failure development [49]. Another known biomarker of myocardium damage is cardiac 602 
troponin I (cTnI), which is released from cardiac myocytes upon their injury. It is used as a 603 
blood biomarker of acute myocardial infarction in humans, but it also has prognostic value in 604 
patients with chronic heart disease [50]. While cTnI concentrations are increased in dogs 605 
with iDCM, there are limitations in its utility since it is not specific to the myocardial injury 606 
cause, can be of normal level in animals with mild disease and is falsely elevated if kidney 607 
injury is present [6]. We observed significant increase of serum cTnI in dogs with iDCM 608 
compared to healthy, as expected. 609 
  610 
Bioinformatics analysis of the in silico inferred protein network enabled us to generate more 611 
information from the experimental results, even providing data on intracellular pathways, 612 
not normally captured by serum proteome analysis. The strength of the in silico inferred 613 
network analysis is reflected in the detection of pathways known to be involved in iDCM, 614 
which indicates validity of the in silico constructed data. Also, recognition of these pathways 615 
has an importance in the possibility of further targeted research. 616 
  617 
Based on the in silico network, we were able to detect ˝The citric acid cycle and respiratory 618 
electron transport˝ as pathway implicated in the disease. This result is consistent with GO 619 
cell localization analysis of the network, which detected ˝inner mitochondrial membrane 620 
protein complex˝ and ¨proton-transporting two-sector ATPase complex¨ GO terms. 621 
Mitochondria, organelles which main function is energy production, are believed to have an 622 
important role in aetiology and/or progression of heart dysfunction pathologies taking into 623 
account myocardium high energy demand [51]. Interestingly, in several studies on heart 624 
tissue of both human and canine iDCM there was a finding of perturbations in mitochondrial 625 
electron transport activity [7,52,53]. Also, when Heinke et al. [54,55] performed proteomic 626 
studies on left ventricular tissue of dogs with pacing-induced heart failure, model state 627 
resembling iDCM, they found impairment of mitochondrial energy production. Furthermore, 628 
Lopes et al. [56] found that most of the altered mitochondrial proteins of heart tissue of 629 
dogs with induced or naturally occurring iDCM, compared to controls, were involved in 630 
respiratory electron transport chain.  631 
Very extensive group of the in silico network analysis was the ˝Signal transduction GPCR 632 
signalling˝, which included ˝G alpha (i) and (z) signalling events˝, ˝Chemokine receptors bind 633 
chemokines˝ and ˝Class C/3 (Metabotropic glutamate/pheromone receptors)˝ pathways. G 634 
protein-coupled receptors (GPCRs) signalling is involved in various physiological pathways 635 
and activated by most of the known neurotransmitters, hormones and chemokines [57]. 636 
GPCRs in turn trigger downstream signalling events, among them G alpha (i) signalling, 637 
reported to be increased in human hearts affected by iDCM, where it seems to mediate 638 
myocardium contractility defects [58]. 639 
Two pathways implicated in iDCM based on the in silico protein network are related to 640 
haemostasis - ˝Formation of Fibrin Clot˝ and ˝Response to elevated platelet cytosolic Ca2+¨.  641 
Activation of coagulation system was found present in humans and dogs with iDCM, possibly 642 
resulting from changes in blood flow due to dilated cardiac chambers and low cardiac output 643 
or as a consequence of activation of the RAAS system [59–61]. Our bioinformatics results are 644 
in accordance with the finding of procoagulant state in dogs with iDCM.  645 
Furthermore, bioinformatics analysis confirmed our observation of immune system 646 
involvement, plasma lipoproteins remodelling and elastic fibre formation in iDCM 647 
physiopathology. One important finding of our study is the supporting evidence of 648 
immunological processes in canine iDCM, which could target the development of new 649 
treatment strategies.  650 
5. CONCLUSIONS  651 
Limitations of this study are small sample size and utilization of samples of the same patients 652 
for validation of proteomics results by Western blot. Therefore, this work can be considered 653 
preliminary and our findings need further validation using different samples and larger 654 
sample size. Nevertheless, we can highlight three putative biomarkers validated herein 655 
which could be relevant for underlying iDCM processes, taking into account the fold change 656 
ratio and high specificity and sensitivity resulting from the analysis of ROC curves. We 657 
propose ITIH4 to be connected with extracellular matrix changes happening upon tissue 658 
injury, which also supports its recently identified role as acute phase protein in dogs [14]. 659 
Furthermore, serum MFAP4 could serve as a biomarker of fibrosis in dogs, whose utility 660 
should be tested in different settings of canine fibrosis in both cardiac and non-cardiac 661 
diseases. Also, low levels of serum APOA4 could be tested as a risk factor for development or 662 
worsening of canine iDCM. Since the data acquired herein could be translational to human 663 
iDCM, these biomarkers may also be of relevance to human patients. In conclusion, label-664 
based high-resolution quantitative proteomics analysis and bioinformatics approach used 665 
herein represent a valid tool for elucidating complex iDCM pathophysiology and uncovering 666 
disease relevant proteins with biomarker potential. 667 
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Figure 1
Figure 1. TMT study design for identification of proteins with biomarker potential and 
pathways involved in canine iDCM (H1, H2 – samples from different healthy dogs; D1, D2 - 
samples from different dogs with iDCM, IS – internal standard sample). 
 
Figure 1 caption
Figure 2
Figure 2. Scatter plots showing the echocardiographic parameters in 8 dogs diagnosed with 
iDCM: a) left ventricular end diastolic diameter (LVIDd) and b) left ventricular end systolic 
diameter (LVIDs). All dogs are above the upper reference values (red lines). 
 
Figure 2 caption
Figure 3
Figure 3. Albumin depletion from canine serum using salt-ethanol procedure. 1-D SDS PAGE 
of a) non-depleted canine serum; b) depleted serum sample of a dog with iDCM; c) depleted 
serum sample of a healthy dog (Notes: a), b) and c) are sera of different dogs; marker and 
samples a) and b) were run on one gel and sample c) on another gel). 
 
 
Figure 3 caption
Figure 4
Figure 4. Comparison of normalized protein abundances ratios between healthy controls, 
iDCM ISACHC class II and class IIIA. 
a) ITIH4 and MFAP4 are up-regulated in iDCM ISACHC class IIIA compared to controls. 
b) APOA4 is down-regulated in iDCM ISACHC class IIIA compared to controls.  
Results are expressed as median and interquartile range, *p < 0.05, **p < 0.01. 
Note that for ITIH4 and APOA4 there are N=8 controls, N=4 iDCM class II, N=4 iDCM class IIIA 
and for MFAP4 N=6 controls, N=3 iDCM class II and N=3 iDCM class IIIA. 
 
Figure 4 caption
Figure 5
Figure 5. Validation of proteomics results:  
a) Representative figures of Western blotting of serum ITIH4, ITIH3, MFAP4, TfR1 and APOA4 
from healthy controls and dogs with iDCM (figures of individual membranes were cropped to 
show the band of interest). 
b) Relative density comparison of the five proteins between healthy controls and iDCM; data 
are shown as mean with SEM, *p < 0.05, **p < 0.01. 
 
Figure 5 caption
Figure 6
Figure 6. Comparison of a) cTnI and b) NT-proBNP blood concentrations between healthy 
dogs and dogs with iDCM. The results are expressed as median and interquartile range.  
Outliers were excluded before statistical analysis based on grubbs’ test for outliers and are 
not shown in the figure (cTnI – 1 outlier in the control group, no outliers in the iDCM group; 
NT-proBNP – no outliers in the control group, 2 outliers in the iDCM group).  
** p < 0.01, *** p<0.001 (compared to the control group)  
 
Figure 6 caption
Figure 7
Figure 7. Design of bioinformatics analysis based on initial list of differential proteins 
between healthy dogs and dogs with iDCM. 
Figure 7 caption
Figure 8
Figure 8. In silico inferred interactome protein network of identified Pathways terms 
involved in canine iDCM. Only nodes interacting with at least 2 terms are represented. 
Organic layout was applied. 
 
 
Figure 8 caption
Figure 9
Figure 9. ROC curves of potential protein biomarkers of iDCM in dogs. Note that there were 
N=8 controls, N=8 iDCM values for ITIH4 and APOA4 analysis; N=6 controls, N=6 iDCM for 
MFAP4 analysis and N=4 controls, N=4 iDCM for ITIH3. 
Figure 9 caption
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